Lupus
Md Yuzaiful Md Yusof Yuz6Yusof
6 days 6 hours ago
#ACR25 Abstr#2411 How good is performance of 2019 ACR-EULAR #SLE criteria at the point of diagnosis in At-Risk ANA+ people? Our group compared this with Clinician dx -> high specificity(93.8%); low sensitivity(79.3%). Might be a cause why SMILE HCQ RCT failed in At-Risk @RheumNow https://t.co/6GNU2B2wvj
Tweeting about an ACR presentation or poster is a skill and sometimes art -- one that is mastered by the RheumNow faculty roving the halls and floors for the best new insights at ACR Convergence 2025. Below are several of the best abstracts from Day 3, as chosen by our outstanding faculty.
Akhil Sood MD, MS AkhilSoodMD
6 days 20 hours ago
A deep dive into Lupus 🔬
Abstract 2601: Single-cell insights in SLE & pre-clinical autoimmunity
🔹 Plasmablast expansion → high disease activity & SLE risk
🔹 Metabolic activity varies by cell type
🔹 Established disease: ↑ glycolysis & OxPHOS changes
@RheumNow #ACR25
Akhil Sood MD, MS AkhilSoodMD
6 days 20 hours ago
Abstract 2360: Single-center lupus pregnancy cohort found that:
🔹 Absence of DORIS remission associated w/ adverse pregnancy outcomes (Pre-term, Pre-eclampsia)
🔹 This is along with known risk factors: antihypertensive use, prior nephritis, active disease
@RheumNow #ACR25 https://t.co/STg1NBeFPo
Bella Mehta bella_mehta
6 days 20 hours ago
Reaadmissions in sle pregnancies from 66k patients
Insurance and economics seem to be very important in predictions using machine learning.
Abst#2629 #ACR25 @RheumNow https://t.co/x2oo9TOxoh
Md Yuzaiful Md Yusof Yuz6Yusof
6 days 20 hours ago
#ACR25 Abstr#2601 At single cell level using CyTOF, metabolic activity varied btw HC & autoimmune groups but clusters in At-Risk ANA+ve appeared closer to #SLE. ANA+ve who progressed to AI-CTD showed Plasmablast expansion & enhanced glycolysis. Could be used as target @RheumNow https://t.co/jtrM1wvQLk
David Liew drdavidliew
6 days 22 hours ago
@RheumNow Obinutuzumab for lupus nephritis was a very recent FDA addition two weeks ago, and we’ll play catch-up with the hematologists to get familiar with it, including its safety profile
#ACR25 FDA Update @RheumNow https://t.co/h6bf4roGzB
Janet Pope Janetbirdope
6 days 22 hours ago
#IL2 #Rx in active #SLE?
Maybe 🤔
IL2 is tricky - low dose May help #SLE but too much of a good thing may have a neg impact.
RCT of IL2i in #SLE gave a good dose response and improved TRegs.
#ACRBest #ACR25 @RheumNow @ACRheum #LB01 https://t.co/F61qz5x5We
Md Yuzaiful Md Yusof Yuz6Yusof
6 days 23 hours ago
#ACR25 Abstr#LB10 Promising 4-Year data of Deucravacitinib in blinded phase 2 RCT +LTE study showed efficacy inc. LLDAS and CLASI-50 response were maintained/improved over time in #SLE No concerning safety signal. Looking forward to Phase 3 results next year @RheumNow https://t.co/fZv82zJ6Q4
Md Yuzaiful Md Yusof Yuz6Yusof
6 days 23 hours ago
#ACR25 How hard will you go & at what cost? A study in China using CD20/BCMA Bispecific autologous CAR-T showed profound depletion, normalisation of abs and good response in #SLE (10/11 had LN). But 2 had G3 infections & cytopenia. Presenters said some had IVIG @RheumNow #ACRBest https://t.co/TF0wpib5rr
Poster Hall